Safir02-breast immuno
WebDec 17, 2024 · Next, Tarantino look to the randomized pooled analysis of phase 2 SAFIR02_BREAST (NCT02299999) and SAFIR-PI3K (NCT03386162) trials, which … WebJan 6, 2024 · A phase II RCT named SAFIR02-BREAST IMMUNO compared durvalumab with chemotherapy (paclitaxel, capecitabine, and FEC) in the maintenance therapy for HER2 …
Safir02-breast immuno
Did you know?
WebMay 22, 2024 · Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to … WebMay 26, 2024 · 1. Abstract 128O ‘PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: exploratory analysis of …
WebDec 7, 2024 · San Antonio Breast Cancer Symposium Source Reference: André F, et al "Clinical utility of molecular tumor profiling: results from the randomized trial SAFIR02 … WebMay 22, 2024 · Methods: SAFIR02 BREAST IMMUNO randomized 199 pts presenting a MBC without actionable genomic alterations, responding to 6 months standard chemotherapy, …
WebThe SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not … WebFeb 25, 2024 · Given as maintenance therapy, the checkpoint inhibitor durvalumab significantly improved overall survival in patients with metastatic triple-negative breast …
WebPD(L)1 inhibitor have shown efficacy for limited sub population of patients (pts) with HER2 negative metastatic breast cancer (MBC). The main predictive marker of efficacy to date …
WebDec 13, 2024 · The SAFIR02-IMMUNO trial, which is a substudy of the SAFIR02_Breast trial (ClinicalTrials.gov Identifier: NCT02299999), included 191 patients with metastatic breast … mariel tresgalloWebDec 8, 2024 · SAFIR02-BREAST (ClinicalTrials.gov Identifier: NCT02299999) is a phase 2 trial that included 1462 patients with metastatic, HER2-negative breast cancer. dali extensionWeb(n = 68) on PFS in the overall population of SAFIR02-BREAST IMMUNO. The HR and P value were derived from a Cox proportional hazard model adjusted for stratification factors: … mariel spa - maria elva - romarellyWebDec 1, 2024 · In patients with metastatic triple-negative breast cancer, atezolizumab combined with immunogenic, anthracycline-based metronomic chemotherapy improves … dali fazon mikro reviewSAFIR02-BREAST IMMUNO is a phase II interventional randomized open-label trial that compares durvalumab (10 mg kg−1 every 2 weeks until progressive disease or toxicity) with maintenance chemotherapy in patients who do not present an actionable genomic alteration. The first patient was randomized … See more Patients signed the informed consent for randomization and were treated either by intravenous durvalumab (10 mg kg−1 every 2 weeks) or … See more The tumor samples were qualified for further genomic testing if more than 30% of the cells in the biopsy sample were cancer cells for frozen … See more ER, PR and Her2 statuses were determined locally. ER and PR thresholds for positivity were set at 1% of tumor cells. ER and PR determinations were assessed on the primary tumor samples. Her2 was defined according to … See more Copy number variations from CytoScan and OncoScan were defined using the R package rCGH31 (v1.16.0, under R v3.6.3). Briefly, log2 relative ratios was calculated, a centralization of the profile set the baseline (two copies … See more dali fazon mikro centre speakerWebAug 1, 2024 · Exploratory analyses from the phase 2 randomized SAFIR02-IMMUNO trial identify biomarkers associated with improved outcomes to durvalumab as compared to … mariel vilellaWebSep 15, 2024 · Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted … mariel vicenzi